# Research Proposal: Multimodal Body Composition Biomarker Knowledge Graph for Precision Oncology

## Executive Summary

We propose to develop a **comprehensive multimodal database and knowledge graph** integrating high-quality internal clinical trial and real-world evidence (RWE) data to advance body composition biomarker discovery in cancer therapy. This initiative will create a **scalable, FAIR-compliant platform** that combines imaging, molecular, clinical, and outcome data to identify novel multimodal biomarkers for treatment selection, toxicity prediction, and outcome optimization. The methodology will be designed as a **generalizable framework** applicable across therapeutic areas including cardiology, metabolism, immunology, and rare disorders.

## Background and Rationale

### Clinical Need

Body composition biomarkers represent an **underutilized resource** in precision oncology, with growing evidence that sarcopenia, visceral adiposity, and muscle quality significantly impact:
- **Drug pharmacokinetics** and dosing optimization
- **Treatment toxicity** and tolerance
- **Therapeutic efficacy** across multiple cancer types
- **Overall survival** and quality of life outcomes

Current clinical practice relies on **body surface area (BSA)** calculations that inadequately capture individual patient variability, leading to suboptimal dosing and increased adverse events.

### Scientific Opportunity

Recent advances in **multimodal data integration** and **knowledge graph technologies** provide unprecedented opportunities to:
- Discover **novel composite biomarkers** combining imaging, molecular, and clinical features
- Identify **mechanistic pathways** linking body composition to treatment outcomes
- Develop **predictive models** for personalized treatment selection
- Create **generalizable methodologies** applicable across disease areas

### Strategic Value

This initiative aligns with AstraZeneca's commitment to **precision medicine** and **data-driven drug development**, providing:
- **Competitive advantage** through proprietary biomarker discovery
- **Enhanced clinical trial design** through better patient stratification
- **Regulatory differentiation** via novel companion diagnostics
- **Platform technology** applicable to multiple therapeutic portfolios

## Objectives

### Primary Objective
Develop a **comprehensive multimodal knowledge graph** integrating body composition imaging, molecular profiling, clinical characteristics, and treatment outcomes from AstraZeneca's internal clinical trials and RWE studies to identify novel biomarkers for cancer therapy optimization.

### Secondary Objectives
1. **Establish standardized data integration pipelines** for multimodal body composition data
2. **Validate novel multimodal biomarkers** for treatment selection and outcome prediction
3. **Create generalizable methodology** applicable across therapeutic areas
4. **Develop clinical decision support tools** for real-time biomarker assessment
5. **Generate intellectual property** through novel biomarker discoveries

## Methodology

### Data Sources and Integration

#### Internal Clinical Trial Data
**Oncology Portfolio Coverage:**
- **Immunotherapy trials** (anti-PD-1/PD-L1, combination therapies)
- **Targeted therapy studies** (kinase inhibitors, ADCs, precision medicines)
- **Chemotherapy trials** with body composition imaging
- **Supportive care studies** including nutrition and exercise interventions

**Data Types for Integration:**
- **Imaging Data**: CT scans (routine staging), DEXA scans, MRI when available
- **Molecular Profiling**: Genomics, transcriptomics, proteomics, metabolomics
- **Clinical Variables**: Demographics, comorbidities, performance status, treatment history
- **Outcome Measures**: Efficacy endpoints, toxicity profiles, survival data, quality of life

#### Real-World Evidence Studies
**External Data Sources:**
- **Electronic health records** with longitudinal imaging data
- **Claims databases** with treatment patterns and outcomes
- **Patient registries** with standardized body composition assessments
- **Biobank samples** with linked clinical and imaging data

### Database Architecture

#### Technical Infrastructure
**Cloud-Native Platform:**
- **Scalable storage** architecture supporting petabyte-scale multimodal data
- **Containerized microservices** for modular data processing pipelines
- **API-first design** enabling seamless integration with existing AZ systems
- **Security framework** ensuring GDPR/HIPAA compliance and data governance

**Data Standardization:**
- **OMOP Common Data Model** for clinical data harmonization
- **DICOM standards** for medical imaging data storage and retrieval
- **HL7 FHIR** for interoperability with clinical systems
- **Genomics standards** (VCF, BAM/SAM) for molecular data integration

#### Knowledge Graph Design
**Ontology Framework:**
- **Custom body composition ontology** extending existing biomedical ontologies
- **SNOMED CT** integration for clinical terminology standardization
- **Gene Ontology** and pathway databases for molecular annotations
- **Imaging ontology** (RadLex) for standardized imaging feature descriptions

**Entity-Relationship Model:**
- **Patient entities** with unique identifiers and privacy protection
- **Imaging entities** with standardized feature extraction and quality metrics
- **Molecular entities** with pathway and functional annotations
- **Treatment entities** with dosing, timing, and response information
- **Outcome entities** with temporal relationships and causality modeling

### Multimodal Biomarker Discovery Pipeline

#### Data Preprocessing and Quality Control
**Imaging Data Processing:**
- **Automated segmentation** algorithms for muscle and adipose tissue quantification
- **Quality assessment** metrics for imaging data inclusion criteria
- **Standardization protocols** for cross-scanner and cross-timepoint comparability
- **Feature extraction** pipelines for radiomics and texture analysis

**Molecular Data Processing:**
- **Batch effect correction** across different platforms and timepoints
- **Missing data imputation** using multimodal approaches
- **Pathway enrichment** analysis for functional interpretation
- **Multi-omics integration** using established and novel methods

#### Machine Learning and AI Framework
**Graph Neural Networks:**
- **Heterogeneous graph** neural networks for multimodal relationship learning
- **Attention mechanisms** for dynamic feature weighting across modalities
- **Temporal graph** networks for longitudinal biomarker evolution
- **Explainable AI** methods for biomarker interpretation and validation

**Multimodal Fusion Strategies:**
- **Early fusion** approaches for joint feature learning
- **Late fusion** methods with ensemble techniques
- **Intermediate fusion** using cross-modal attention and transformers
- **Hierarchical fusion** for multi-scale biomarker discovery

### Validation Framework

#### Internal Validation
**Cross-Validation Strategies:**
- **Temporal validation** using chronologically separated datasets
- **Geographic validation** across different study sites and populations
- **Therapeutic validation** across different treatment modalities
- **Molecular subtype** validation within cancer-specific cohorts

#### External Validation
**Independent Cohort Validation:**
- **Academic collaborations** for external dataset access
- **Public database** validation using TCGA, UK Biobank, and other resources
- **Prospective validation** in ongoing clinical trials
- **Real-world validation** using external RWE datasets

### Generalizability Framework

#### Cross-Therapeutic Area Applications
**Methodology Adaptation:**
- **Cardiovascular applications**: Heart failure, cardiomyopathy, cardiac toxicity
- **Metabolic disorders**: Diabetes, obesity, metabolic syndrome
- **Immunological conditions**: Autoimmune diseases, transplant medicine
- **Rare disorders**: Muscular dystrophies, metabolic myopathies

**Platform Scalability:**
- **Modular architecture** enabling rapid deployment across therapeutic areas
- **Standardized APIs** for integration with existing therapeutic area databases
- **Configurable ontologies** adaptable to different disease contexts
- **Transferable ML models** with domain adaptation capabilities

## Work Packages and Timeline

### Phase 1: Infrastructure Development (Months 1-12)
**WP1.1: Data Architecture and Integration (Months 1-6)**
- Database design and cloud infrastructure setup
- Data ingestion pipelines for clinical trial and RWE data
- Quality control and standardization protocols
- Security and compliance framework implementation

**WP1.2: Knowledge Graph Construction (Months 4-12)**
- Ontology development and integration
- Entity extraction and relationship mapping
- Graph database implementation and optimization
- API development for data access and querying

### Phase 2: Biomarker Discovery and Validation (Months 6-24)
**WP2.1: Multimodal Data Integration (Months 6-15)**
- Imaging data processing and feature extraction
- Molecular data integration and pathway analysis
- Clinical data harmonization and outcome modeling
- Cross-modal relationship identification

**WP2.2: Machine Learning Pipeline Development (Months 9-21)**
- Graph neural network implementation and training
- Multimodal fusion algorithm development
- Biomarker discovery and ranking algorithms
- Model interpretation and explainability tools

**WP2.3: Biomarker Validation (Months 15-24)**
- Internal cross-validation across datasets
- External validation using independent cohorts
- Clinical utility assessment and outcome prediction
- Regulatory pathway evaluation

### Phase 3: Platform Generalization and Deployment (Months 18-36)
**WP3.1: Cross-Therapeutic Area Adaptation (Months 18-30)**
- Cardiovascular application development
- Metabolic disorder use case implementation
- Immunology and rare disease pilot studies
- Platform scalability testing and optimization

**WP3.2: Clinical Decision Support Tools (Months 24-36)**
- Real-time biomarker calculation algorithms
- Clinical workflow integration
- User interface development for clinical teams
- Pilot deployment in clinical settings

## Expected Outcomes and Deliverables

### Scientific Deliverables
**Novel Biomarker Discoveries:**
- **Composite biomarkers** combining imaging, molecular, and clinical features
- **Mechanistic insights** into body composition effects on drug response
- **Predictive models** for treatment selection and outcome optimization
- **Temporal biomarkers** capturing treatment response dynamics

**Publications and Presentations:**
- **High-impact publications** in journals such as Nature Medicine, Cell, Lancet Oncology
- **Conference presentations** at ASCO, ESMO, AACR, and AI/ML venues
- **Regulatory submissions** for novel biomarker qualification
- **Patent applications** for proprietary biomarker discoveries

### Technical Deliverables
**Platform and Tools:**
- **Scalable multimodal database** with standardized APIs
- **Knowledge graph** with comprehensive biomedical relationships
- **Machine learning pipelines** for automated biomarker discovery
- **Clinical decision support** tools for real-time assessment

**Intellectual Property:**
- **Novel biomarker compositions** and their clinical applications
- **Algorithmic innovations** in multimodal data integration
- **Platform technologies** applicable across therapeutic areas
- **Clinical utility demonstrations** for regulatory approval

### Business Impact
**Competitive Advantages:**
- **Proprietary biomarker portfolio** for precision medicine applications
- **Enhanced clinical trial design** through better patient stratification
- **Regulatory differentiation** via novel companion diagnostics
- **Platform technology** licensing opportunities

**Clinical Applications:**
- **Improved treatment selection** reducing trial-and-error approaches
- **Optimized dosing strategies** minimizing toxicity while maximizing efficacy
- **Enhanced patient outcomes** through personalized treatment approaches
- **Reduced healthcare costs** via more efficient treatment selection

## Budget and Resources

### Personnel Requirements
**Core Team (36 months):**
- **Principal Investigator** (1.0 FTE): Project leadership and scientific oversight
- **Data Scientists** (3.0 FTE): Machine learning and biomarker discovery
- **Bioinformaticians** (2.0 FTE): Multi-omics data integration and analysis
- **Software Engineers** (2.0 FTE): Platform development and deployment
- **Clinical Scientists** (1.5 FTE): Clinical data interpretation and validation
- **Data Engineers** (1.5 FTE): Database architecture and data pipelines

**Specialized Expertise:**
- **Imaging Scientists** (1.0 FTE): Radiomics and image analysis
- **Statisticians** (1.0 FTE): Study design and validation methodology
- **Regulatory Affairs** (0.5 FTE): Biomarker qualification and submission
- **Clinical Operations** (0.5 FTE): Data access and clinical workflow integration

### Infrastructure and Technology
**Cloud Computing Resources:**
- **Data storage**: Estimated 500TB for multimodal datasets
- **Compute resources**: GPU clusters for deep learning and graph analysis
- **Database licensing**: Enterprise graph database and analytics platforms
- **Security and compliance**: Data governance and privacy protection tools

**External Collaborations:**
- **Academic partnerships** for external validation datasets
- **Technology vendors** for specialized software and platforms
- **Regulatory consultants** for biomarker qualification guidance
- **Clinical sites** for prospective validation studies

### Estimated Budget
**Total Project Cost: $8.5M over 36 months**

**Personnel (65% - $5.5M):**
- Core team salaries and benefits
- Specialized consultant fees
- Training and development costs

**Technology and Infrastructure (25% - $2.1M):**
- Cloud computing and storage costs
- Software licensing and development tools
- Hardware for specialized processing

**External Collaborations (10% - $0.9M):**
- Academic partnership agreements
- External validation study costs
- Regulatory consultation fees

## Risk Assessment and Mitigation

### Technical Risks
**Data Quality and Integration Challenges:**
- **Risk**: Heterogeneous data quality across studies and timepoints
- **Mitigation**: Robust quality control pipelines and standardized preprocessing protocols

**Scalability and Performance Issues:**
- **Risk**: Platform performance degradation with increasing data volume
- **Mitigation**: Cloud-native architecture with auto-scaling capabilities and performance monitoring

### Scientific Risks
**Biomarker Validation Failures:**
- **Risk**: Discovered biomarkers may not validate in independent cohorts
- **Mitigation**: Rigorous cross-validation strategies and external validation planning

**Limited Generalizability:**
- **Risk**: Biomarkers may be specific to particular populations or treatment contexts
- **Mitigation**: Diverse dataset inclusion and systematic generalizability testing

### Regulatory and Commercial Risks
**Regulatory Approval Challenges:**
- **Risk**: Novel multimodal biomarkers may face regulatory uncertainty
- **Mitigation**: Early engagement with regulatory agencies and established qualification pathways

**Intellectual Property Conflicts:**
- **Risk**: Potential IP conflicts with external parties or prior art
- **Mitigation**: Comprehensive IP landscape analysis and strategic patent filing

## Success Metrics and Key Performance Indicators

### Scientific Success Metrics
**Biomarker Discovery:**
- **Number of validated biomarkers** with clinical utility demonstration
- **Predictive performance** improvement over existing biomarkers (AUC > 0.8)
- **Cross-therapeutic area** applicability demonstration (≥3 therapeutic areas)

**Publication and Recognition:**
- **High-impact publications** (≥5 papers in journals with IF > 10)
- **Patent applications** filed (≥10 novel biomarker compositions)
- **Regulatory interactions** initiated (≥2 biomarker qualification discussions)

### Technical Success Metrics
**Platform Performance:**
- **Data integration** completeness (>90% of available datasets)
- **Query response time** for complex multimodal queries (<5 seconds)
- **Platform uptime** and reliability (>99.5% availability)

**User Adoption:**
- **Internal user** engagement across therapeutic areas (>50 active users)
- **API usage** statistics and integration success (>1000 queries/month)
- **Clinical workflow** integration pilots (≥3 successful implementations)

### Business Success Metrics
**Commercial Impact:**
- **Clinical trial** efficiency improvements (20% reduction in patient screening time)
- **Treatment optimization** demonstrations (15% improvement in response rates)
- **Cost savings** through better patient selection ($10M+ in avoided failed treatments)

**Strategic Value:**
- **Partnership opportunities** generated through platform capabilities
- **Licensing revenue** potential from cross-therapeutic applications
- **Competitive differentiation** in precision medicine portfolio

## Conclusion

This research proposal presents a **transformative opportunity** to advance precision oncology through the development of a comprehensive multimodal biomarker discovery platform. By integrating AstraZeneca's rich internal datasets with cutting-edge knowledge graph technologies, we will create **novel composite biomarkers** that significantly improve treatment selection and patient outcomes.

The **generalizable methodology** ensures broad applicability across therapeutic areas, providing a **strategic platform technology** that enhances AstraZeneca's competitive position in precision medicine. The proposed timeline, budget, and risk mitigation strategies provide a realistic pathway to achieving these ambitious goals while maintaining scientific rigor and regulatory compliance.

**Success in this initiative will position AstraZeneca as a leader in multimodal biomarker discovery, creating lasting competitive advantages and improving patient outcomes across multiple therapeutic areas.**

Would you like me to elaborate on any specific section of this proposal or discuss particular technical aspects in more detail?